Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 326-330
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.326
Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards
Michael Horowitz, Lu Cai, Md Shahidul Islam
Michael Horowitz, Department of Medicine, University of Adelaide, Adelaide 5005, Australia
Lu Cai, Pediatric Research Institute, University of Louisville, Louisville, KY 40202, United States
Md Shahidul Islam, Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Durban 4000, KwaZulu-Natal, South Africa
Author contributions: Horowitz M conceptualised and wrote the first draft of the editorial; Islam MS and Cai L made revisions and editorial corrections before submission; All authors have read and approved the final manuscript.
Conflict-of-interest statement: Horowitz M, Cai L and Islam MS have no conflict of interest within this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Horowitz, MBBS, PhD, DSc, FRACP, AO, Director, Endocrine and Metabolic Unit, Royal Adelaide Hospital and Professor, Department of Medicine, University of Adelaide, Level 5, AHMS Corner North Tce and George St, Adelaide 5005, Australia. michael.horowitz@adelaide.edu.au
Received: January 28, 2024
Peer-review started: January 28, 2024
First decision: February 8, 2024
Revised: February 14, 2024
Accepted: February 23, 2024
Article in press: February 23, 2024
Published online: March 15, 2024
Core Tip

Core Tip: In people who are prescribed a glucagon-like-peptide-1 receptor agonist (GLP-1RA) for management of type 2 diabetes or obesity you should always ask about gastrointestinal symptoms both before and after initiating therapy. Gastrointestinal adverse effects of GLP-1RAs are common, but may not be volunteered.